Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
London pre-open: Stocks seen lower as investors eye Budget
(Sharecast News) - London stocks were set to edge down at the open on Monday as investors turned their attention to this week's Budget. The FTSE 100 was called to open around 15 points lower.
On Wednesday, Chancellor Jeremy Hunt will present the Spring Budget to Parliament at 1230 GMT in what is likely to be the last major economic update before the upcoming general election.
Kathleen Brooks, research director at XTB, said: "The showpiece is expected to be a 2p cut to the national insurance rate, however, the chancellor gives with one hand, but he is likely to take away with another.
"Reports on Monday suggest that he has pencilled in plans to recoup £9bn through tax rises and spending cuts, in order to pay for the cut in NI. The fiscal headroom available to the Chancellor is expected to be £20bn, which is lower than the average of nearly £30bn available since 2010, and highlights the fiscal tight spot the UK finds itself in.
"After the NI cut, the chancellor may only have £10-15bn left to give away election sweeteners to try and boost votes for the Tories. This is the ultimate election budget, with a bit of fiscal prudence thrown in. However, because the Tories are on track to lose this election, there is also a sense that this Budget may not be worth the paper that it is written on, as any tax and spending changes could be reversed by the next government.
"There are two other factors to consider alongside this Budget. The Chancellor is not going to want to do anything that could make an interest rate cut from the BOE less likely, as this could be more important for winning votes than future tax giveaways. This means that we don't expect any major changes on Wednesday. Also, the OBR forecasts will be worth watching. Will they revise down growth forecasts to bring them more in line with the BOE? Could inflation be revised up? Either way, the OBR forecasts may paint the UK economy in an unflattering light."
Brooks said she does not expect the Budget to move the dial for UK equities, which are struggling from their lack of exposure to tech and AI.
In corporate news, Aviva made its first foray into the Lloyd's insurance market with the £242m purchase of underwriting syndicate Probitas.
The deal includes the acquisition of Probitas's Lloyd's platform, taking in its corporate member, managing agent, international distribution entities and tenancy rights to Syndicate 1492, Aviva said.
Intertek announced its acquisition of Base Metallurgical Laboratories, a provider of metallurgical testing services in North America, for an undisclosed sum.
The FTSE 100 firm said the acquisition would strengthen its position in the industry by expanding its geographic footprint and complementing its existing capabilities in geochemistry, mine site laboratories, and trade inspection.
With a focus on critical metals like gold and copper, it said Base Met Labs aligned with the increasing demand for minerals testing, particularly in battery and energy metals.
European regulators have validated two marketing authorisation applications for AstraZeneca, as the biopharma giant's datopotamab deruxtecan product comes one step closer to receiving the green light to treat two types of cancer.
The validations confirm the completion of the applications and will kickstart the scientific review process by the European Medicines Agency's Committee for Medicinal Products for Human Use.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.